{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:10:38Z","timestamp":1778670638843,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005349","name":"American Association of Colleges of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009612","name":"Oregon State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jconrel.2019.06.036","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T12:02:10Z","timestamp":1561723330000},"page":"272-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment"],"prefix":"10.1016","volume":"307","author":[{"given":"Bhuvana S.","family":"Doddapaneni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel M.","family":"AL-Fatease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa A.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-9317","authenticated-orcid":false,"given":"Adam W.G.","family":"Alani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2014.12.003","article-title":"Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy","volume":"41","author":"Della Pepa","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2019.06.036_bb0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00004650-200311000-00005","article-title":"The silent killer: psychological issues in ovarian cancer","volume":"17","author":"McCorkle","year":"2003","journal-title":"Holist. Nurs. Pract."},{"issue":"1","key":"10.1016\/j.jconrel.2019.06.036_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007950300002","article-title":"Histological classification of ovarian cancer","volume":"36","author":"Kaku","year":"2003","journal-title":"Med. Electron Microsc."},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jcp.2007.049478","article-title":"My approach to and thoughts on the typing of ovarian carcinomas","volume":"61","author":"McCluggage","year":"2008","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jconrel.2019.06.036_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/WHE.10.48","article-title":"Targeted agents in ovarian cancer","volume":"6","author":"Kristedja","year":"2010","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.jconrel.2019.06.036_bb0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biomaterials.2014.10.044","article-title":"Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment","volume":"37","author":"Cai","year":"2015","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00001622-200009000-00016","article-title":"Advances in ovarian cancer chemotherapy","volume":"12","author":"Deppe","year":"2000","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.2659","article-title":"Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma","volume":"220","author":"Madore","year":"2010","journal-title":"J. Pathol."},{"issue":"11","key":"10.1016\/j.jconrel.2019.06.036_bb0060","doi-asserted-by":"crossref","first-page":"13153","DOI":"10.18632\/oncotarget.7549","article-title":"Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.jconrel.2019.06.036_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.18632\/aging.100202","article-title":"TP53 and MTOR crosstalk to regulate cellular senescence","volume":"2","author":"Galluzzi","year":"2010","journal-title":"Aging (Albany NY)"},{"issue":"22","key":"10.1016\/j.jconrel.2019.06.036_bb0070","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1158\/1078-0432.CCR-12-0406","article-title":"Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model","volume":"18","author":"van der Bilt","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2019.06.036_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11523-011-0179-4","article-title":"The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas","volume":"6","author":"Vemulapalli","year":"2011","journal-title":"Target. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2019.06.036_bb0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ijgc-00009577-200602001-00075","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer","volume":"16","author":"Jiang","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.jconrel.2019.06.036_bb0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s12885-015-1539-8","article-title":"Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer","volume":"15","author":"McEvoy","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0090","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1535-7163.647.3.5","article-title":"Hypoxia inducible factor-1alpha as a cancer drug target","volume":"3","author":"Powis","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2407-7-213","article-title":"Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells","volume":"7","author":"Staab","year":"2007","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2019.06.036_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0105","first-page":"299","article-title":"mTOR as a positive regulator of tumor cell responses to hypoxia","volume":"279","author":"Abraham","year":"2004","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/1471-2407-10-605","article-title":"HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression","volume":"10","author":"Kessler","year":"2010","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2019.06.036_bb0115","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/ijc.27448","article-title":"Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene","volume":"131","author":"Horiuchi","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2019.06.036_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2004.06.009","article-title":"Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway","volume":"6","author":"Kung","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2014.02.017","article-title":"mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review","volume":"133","author":"Husseinzadeh","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"36","key":"10.1016\/j.jconrel.2019.06.036_bb0130","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.2174\/138161206779026245","article-title":"Polymeric micelles for drug delivery","volume":"12","author":"Croy","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2015.12.031","article-title":"Recent advances in polymeric micelles for anti-cancer drug delivery","volume":"83","author":"Biswas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jconrel.2009.04.024","article-title":"Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs","volume":"140","author":"Shin","year":"2009","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.jconrel.2019.06.036_bb0145","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/ma200675w","article-title":"Stability of self-assembled polymeric micelles in serum","volume":"44","author":"Lu","year":"2011","journal-title":"Macromolecules"},{"issue":"6","key":"10.1016\/j.jconrel.2019.06.036_bb0150","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1248\/bpb.35.975","article-title":"Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma","volume":"35","author":"Iwase","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/2230-973X.160846","article-title":"Synthesis and self-assembly of biodegradable polyethylene glycol-poly (lactic acid) diblock copolymers as polymersomes for preparation of sustained release system of doxorubicin","volume":"5","author":"Alibolandi","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0160","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11095-013-1188-z","article-title":"Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers","volume":"31","author":"Mishra","year":"2014","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2019.06.036_bb0165","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/mp2000549","article-title":"A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs","volume":"8","author":"Shin","year":"2011","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1208\/s12249-012-9782-7","article-title":"Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies","volume":"13","author":"Awotwe-Otoo","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13346-013-0129-z","article-title":"In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges","volume":"3","author":"Shen","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2019.06.036_bb0180","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/jclinpath-2014-202430","article-title":"Caution over use of ES2 as a model of ovarian clear cell carcinoma","volume":"67","author":"Kwok","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0185","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jconrel.2019.06.036_bb0195","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2015.06.040","article-title":"Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo","volume":"213","author":"Cote","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejpb.2006.11.009","article-title":"A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes","volume":"65","author":"Letchford","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.jconrel.2019.06.036_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1166\/jbn.2015.1919","article-title":"Development of RGD-functionalized PEG-PLA micelles for delivery of curcumin","volume":"11","author":"Zhao","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2019.06.036_bb0210","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/5\/055106","article-title":"PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations","volume":"20","author":"Li","year":"2009","journal-title":"Nanotechnology"},{"issue":"20","key":"10.1016\/j.jconrel.2019.06.036_bb0215","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1039\/C4NR02978J","article-title":"Enhanced antitumor activity and mechanism of biodegradable polymeric micelles-encapsulated chetomin in both transgenic zebrafish and mouse models","volume":"6","author":"Wu","year":"2014","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals","volume":"3","author":"O'Reilly","year":"2010","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2019.06.036_bb0225","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jconrel.2019.06.036_bb0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"8","key":"10.1016\/j.jconrel.2019.06.036_bb0235","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.jconrel.2019.06.036_bb0240","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1039\/c2nr32181e","article-title":"Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer","volume":"4","author":"Gao","year":"2012","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.jconrel.2019.06.036_bb0245","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/molecules20022323","article-title":"Targeting carbonic anhydrase IX activity and expression","volume":"20","author":"Mahon","year":"2015","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.jconrel.2019.06.036_bb0250","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev."},{"issue":"5322","key":"10.1016\/j.jconrel.2019.06.036_bb0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.277.5322.99","article-title":"Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin","volume":"277","author":"Brunn","year":"1997","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919303694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919303694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:44:51Z","timestamp":1759160691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919303694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":51,"alternative-id":["S0168365919303694"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}